<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>FDA Approval on FinanClub</title>
    <link>https://finan.club/tags/fda-approval/</link>
    <description>Recent content in FDA Approval on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Mon, 11 Sep 2023 05:49:37 +0000</lastBuildDate><atom:link href="https://finan.club/tags/fda-approval/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>GILD</title>
      <link>https://finan.club/us/gild/</link>
      <pubDate>Mon, 11 Sep 2023 05:49:37 +0000</pubDate>
      
      <guid>https://finan.club/us/gild/</guid>
      <description>score:60
Chances: Gilead&amp;rsquo;s Phase 2 EVOKE-02 Study of Trodelvy in Combination with KEYTRUDA demonstrates promising clinical activity in first-line metastatic non-small cell lung cancer, indicating potential growth opportunities. Gilead Sciences has a high institutional ownership of 86%, suggesting confidence from major investors. The FDA approval for Veklury to treat COVID-19 in people with hepatic impairment is a positive development for Gilead&amp;rsquo;s product portfolio.</description>
    </item>
    
    <item>
      <title>VTRS</title>
      <link>https://finan.club/us/vtrs/</link>
      <pubDate>Mon, 11 Sep 2023 05:39:30 +0000</pubDate>
      
      <guid>https://finan.club/us/vtrs/</guid>
      <description>score:-49
Chances: Viatris Inc. (VTRS) has been gaining attention as a pharmaceutical stock that may be undervalued. The company recently received tentative approval from the FDA for a pediatric HIV regimen, which could open new revenue streams. Viatris reported strong Q2 2023 earnings with growth in its generics business, indicating positive performance.</description>
    </item>
    
    <item>
      <title>BMY</title>
      <link>https://finan.club/us/bmy/</link>
      <pubDate>Mon, 11 Sep 2023 05:08:33 +0000</pubDate>
      
      <guid>https://finan.club/us/bmy/</guid>
      <description>score:93
Chances: Bristol-Myers Squibb&amp;rsquo;s investigational LPA1 antagonist shows promise in reducing lung function decline in a Phase 2 study, which could lead to a potential breakthrough in pulmonary fibrosis treatment. Bristol-Myers Squibb celebrates a decade of its Coast 2 Coast 4 Cancer cross-country bike ride in support of the V Foundation for Cancer Research, showcasing its commitment to corporate social responsibility.</description>
    </item>
    
  </channel>
</rss>
